Matches in Wikidata for { <http://www.wikidata.org/entity/Q66392628> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66392628 description "clinical trial" @default.
- Q66392628 description "ensayu clínicu" @default.
- Q66392628 description "klinisch onderzoek" @default.
- Q66392628 description "клінічне випробування" @default.
- Q66392628 name "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma" @default.
- Q66392628 name "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma" @default.
- Q66392628 type Item @default.
- Q66392628 label "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma" @default.
- Q66392628 label "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma" @default.
- Q66392628 prefLabel "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma" @default.
- Q66392628 prefLabel "Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma" @default.
- Q66392628 P1050 Q66392628-10D19455-7EA4-4C75-8E6D-9E7B50172A66 @default.
- Q66392628 P1050 Q66392628-8B3B171A-6E74-46CC-AB83-0D942451F853 @default.
- Q66392628 P1132 Q66392628-1D985670-AC1F-438A-B135-2E198C2D26B7 @default.
- Q66392628 P1476 Q66392628-BE85DB14-A287-439B-A703-10BD78DAEEB5 @default.
- Q66392628 P17 Q66392628-EBF42E68-09BC-4DC9-9039-CBE85422E303 @default.
- Q66392628 P2899 Q66392628-7F7E0C38-181B-4E72-BB41-421663673E2F @default.
- Q66392628 P3098 Q66392628-774F28D5-5810-4862-9175-3C744292B0C3 @default.
- Q66392628 P31 Q66392628-788504AC-B1F4-464A-A8D5-BA0457221B64 @default.
- Q66392628 P4844 Q66392628-F64FB61D-A2E5-42CC-A166-685405569DB5 @default.
- Q66392628 P580 Q66392628-3FFC749A-AC1F-46A7-939B-01388FEBC84C @default.
- Q66392628 P582 Q66392628-EF06FEDB-EB36-4410-8CDF-44B752800F4D @default.
- Q66392628 P6099 Q66392628-5608224D-62BE-4D9B-8A14-34C5013F73DD @default.
- Q66392628 P6099 Q66392628-9110E2BF-6BCA-4B83-AC3F-A57F8CB9A81B @default.
- Q66392628 P8363 Q66392628-BB23A5CE-B7D6-4AEA-B73A-A2BC65979F43 @default.
- Q66392628 P1050 Q1891209 @default.
- Q66392628 P1050 Q208414 @default.
- Q66392628 P1132 "+62" @default.
- Q66392628 P1476 "A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma" @default.
- Q66392628 P17 Q30 @default.
- Q66392628 P2899 "+18" @default.
- Q66392628 P3098 "NCT03011814" @default.
- Q66392628 P31 Q30612 @default.
- Q66392628 P4844 Q425681 @default.
- Q66392628 P580 "2017-03-08T00:00:00Z" @default.
- Q66392628 P582 "2019-09-01T00:00:00Z" @default.
- Q66392628 P6099 Q42824440 @default.
- Q66392628 P6099 Q5452194 @default.
- Q66392628 P8363 Q78089383 @default.